American Journal of Ophthalmology
Volume 137, Issue 1 , Pages 38-42 , January 2004

Endophthalmitis isolates and antibiotic sensitivities: a 6-year review of culture-proven cases

  • Matthew S. Benz, MD

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA
    • Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, USA (M.S.B.)
    • Corresponding Author InformationInquiries to Matthew S. Benz, MD, Cullen Eye Institute, 6565 Fannin, NC-205, Houston, TX 77030, USA; fax: (713) 798-0120
    • ,
  • Ingrid U. Scott, MD, MPH

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA
    • ,
  • Harry W. Flynn Jr, MD

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA
    • ,
  • Nichard Unonius, MD

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA
    • ,
  • Darlene Miller, MPH, MA

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA

,Accepted 29 July 2003.

References 

  1. Han DP, Wisniewski SR, Wilson LA, et al.  Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122:1–17
  2. Johnson MW, Doft BH, Kelsey SF, et al.  The Endophthalmitis Vitrectomy Study. Relationship between clinical presentation and microbiologic spectrum. Ophthalmology. 1997;104:261–272
  3. Endophthalmitis Vitrectomy Study Group . Microbiologic factor and visual outcome in the endophthalmitis vitrectomy study. Am J Ophthalmol. 1996;122:830–846
  4. Roth DB, Flynn HW. Antibiotic selection in the treatment of endophthalmitis (the significance of drug combinations and synergy). Surv Ophthalmol. 1997;41:395–401
  5. Kunimoto DY, Das T, Sharma S, et al.  Microbiologic spectrum and susceptibility of isolates (part I. Postoperative endophthalmitis. Endophthalmitis Research Group). Am J Ophthalmol. 1999;128:240–242
  6. Kangas TA, Greenfield DS, Flynn HW, Parrish RK, Palmberg PF. Delayed-onset endophthalmitis associated with conjunctival filtering blebs. Ophthalmology. 1997;104:746–752
  7. Song A, Scott IU, Flynn HW, Budenz DL. Delayed-onset bleb-associated endophthalmitis (clinical features and visual acuity outcomes). Ophthalmology. 2002;109:985–991
  8. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery (an evidence-based update). Ophthalmology. 2002;109:13–26
  9. Leaming DV. Practice styles and preferences of ASCRS members—2000 survey. American Society of Cataract and Refractive Surgery. J Cataract Refract Surg. 2001;27:948–955
  10. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497–1502
  11. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis (a 5-year review). Ophthalmology. 1999;106:1313–1318
  12. Anand AR, Therese KL, Madhavan HN. Spectrum of aetiologic agents of postoperative endophthalmitis and antibiotic sensitivity of bacterial isolates. Indian J Ophthalmol. 2000;48:123–128
  13. Odenholt I, Lowdin E, Cars O. Bactericidal effects of levofloxacin in comparison with those of ciprofloxacin and sparfloxacin. Clin Microbiol Infect. 1998;4:264–270
  14. Lesk MR, Ammann H, Marcil G, et al.  Penetration of oral ciprofloxacin into the aqueous humor, vitreous, and subretinal fluid of humans. Am J Ophthalmol. 1993;115:623–628
  15. Ozturk F, Kurt E, Inan UU, et al.  Penetration of topical and oral ofloxacin into the aqueous and vitreous humor of inflamed rabbit eyes. Int J Pharm. 2000;204:91–95
  16. Fiscella RG, Nguyen TK, Cwik MJ, et al.  Aqueous and vitreous penetration of levofloxacin after oral administration. Ophthalmology. 1999;106:2286–2290
  17. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones (new weapons in the arsenal of ophthalmic antibiotics (1)). Am J Ophthalmol. 2002;133:463–466
  18. Harispaad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch Ophthalmol. 2003;121:345–350
  19. Gordon YJ. Vancomycin prophylaxis and emerging resistance (are ophthalmologists the villains? The heroes?). Am J Ophthalmol. 2001;131:371–376

☆ This study was supported in part by Research to Prevent Blindness, Inc, New York, New York.

PII: S0002-9394(03)00896-1

doi: 10.1016/S0002-9394(03)00896-1

American Journal of Ophthalmology
Volume 137, Issue 1 , Pages 38-42 , January 2004

Article Tools